Vol 73, No 1 (2022)
Original paper
Published online: 2022-02-15

open access

Page views 5820
Article views/downloads 660
Get Citation

Connect on Social Media

Connect on Social Media

The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes

Jarosław Sobiś1, Łukasz Kunert1, Monika Rykaczewska-Czerwińska2, Elżbieta Świętochowska3, Piotr Gorczyca1
Pubmed: 35381103
Endokrynol Pol 2022;73(1):35-42.


Introduction: The aim of this study was to test the effect of aripiprazole on leptin, insulin, acute phase proteins, and selected cytokines levels in patients with chronic schizophrenia. Additionally, levels of leptin, insulin, acute phase proteins, and cytokines were compared with body mass and body composition indexes.

Material and methods: Levels of leptin, insulin, serum amyloid A (SAA), tumour necrosis factor alpha (TNF-α), and interleukins 17A (IL-17A) and 18 (IL-18) in blood serum were measured for 17 patients before and after 28 days of administering aripiprazole by means of enzyme-linked immunosorbent assay (ELISA). Before and after the study, body mass and waist circumference (WC) were also measured, and body mass index (BMI) and body fat percentage (BF%) were estimated. The sex of each patient was taken into account.

Results: After administration of aripiprazole the reduction of levels of leptin, insulin, SAA, and TNF-a were statistically significant, similarly to body mass reduction and decrease in WC, BMI, and BF%, which were also statistically significant. A positive correlation between leptin and BF% and negative correlation between insulin and body mass and body composition indexes were observed before and after the study. High sensitivity C-reactive protein (hsCRP) and  hsCRP/albumin positively correlated with BMI before the treatment. In the group of women a statistically significant positive correlation between TNF-α and IL-17A and body mass and body composition indexes was observed, and in the group of men a negative correlation between IL-18 and BMI, WC, and BF% was noted.

Conclusions: The effect of aripiprazole is connected to its anti-inflammatory activity. A 28-day treatment resulted in reduction of adipose tissue, and in the group of women it returned their leptin sensitivity to normal levels. A change of psychotropic treatment and administration of aripiprazole reduces cardiometabolic risks.

Article available in PDF format

View PDF Download PDF file


  1. Meyer JM, McEvoy JP, Davis VG, et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry. 2009; 66(11): 1013–1022.
  2. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol. 2011; 14(7): 997–1012.
  3. O'Connell KE, Thakore J, Dev KK. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophr Res. 2014; 156(1): 1–8.
  4. Kluge M, Schuld A, Schacht A, et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology. 2009; 34(1): 118–128.
  5. Löffler S, Löffler-Ensgraber M, Fehsel K, et al. Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int Clin Psychopharmacol. 2010; 25(2): 101–106.
  6. Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014; 9(4): e94112.
  7. Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology. 2007; 32(4): 765–772.
  8. Albaugh VL, Judson JG, She P, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry. 2011; 16(5): 569–581.
  9. Starrenburg FCJ, Bogers JP. How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry. 2009; 24(3): 164–170.
  10. Newcomer JW, Lieberman JA, Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004; 26(12): 1936–1946.
  11. Bays HE, González-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008; 6(3): 343–368.
  12. Ghigliotti G, Barisione C, Garibaldi S, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation. 2014; 37(4): 1337–1353.
  13. Stachowicz M, Janas-Kozik M, Olszanecka-Glinianowicz M, et al. Rola leptyny w zaburzeniach odżywiania się – współczesne poglądy. Psychiatr Pol. 2013; 47(5): 897–907.
  14. Van Harmelen V, Reynisdottir S, Eriksson P, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes. 1998; 47(6): 913–917.
  15. Couillard C, Mauriège P, Prud'homme D, et al. Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease. Diabetologia. 1997; 40(10): 1178–1184.
  16. Fernández-Riejos P, Najib S, Santos-Alvarez J, et al. Role of leptin in the activation of immune cells. Mediators Inflamm. 2010; 2010: 568343.
  17. Chen Ke, Li F, Li Ji, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006; 12(4): 425–432.
  18. Wang S, Reed DB, Goli S, et al. Blood leptin and C-reactive protein provide more sensitive assessment than blood lipids and other inflammatory biomarkers in overweight university students. Nutr Res. 2011; 31(8): 586–593.
  19. Wozniak SE, Gee LL, Wachtel MS, et al. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009; 54(9): 1847–1856.
  20. Sentissi O, Epelbaum J, Olié JP, et al. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull. 2008; 34(6): 1189–1199.
  21. Endomba FT, Tankeu AT, Nkeck JR, et al. Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis. 2020; 19(1): 22.
  22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.
  23. Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond). 2012; 36(2): 286–294.
  24. Kyle UG, Schutz Y, Dupertuis YM, et al. Body composition interpretation. Contributions of the fat-free mass index and the body fat mass index. Nutrition. 2003; 19(7-8): 597–604.
  25. Guerrero-Romero F, Bermudez-Peña C, Rodríguez-Morán M. Severe hypomagnesemia and low-grade inflammation in metabolic syndrome. Magnes Res. 2011; 24(2): 45–53.
  26. Faty A, Ferré P, Commans S. The acute phase protein Serum Amyloid A induces lipolysis and inflammation in human adipocytes through distinct pathways. PLoS One. 2012; 7(4): e34031.
  27. Askari H, Tykodi G, Liu J, et al. Fasting plasma leptin level is a surrogate measure of insulin sensitivity. J Clin Endocrinol Metab. 2010; 95(8): 3836–3843.
  28. Maachi M, Piéroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord. 2004; 28(8): 993–997.
  29. Sobiś J, Rykaczewska-Czerwińska M, Świętochowska E, et al. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacol Rep. 2015; 67(2): 353–359.
  30. Phillips CM, Tierney AC, Perez-Martinez P, et al. Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype. Obesity (Silver Spring). 2013; 21(1): E154–E161.
  31. Sharpe JK, Byrne NM, Stedman TJ, et al. Comparison of clinical body composition methods in people taking weight-inducing atypical antipsychotic medications. Asia Pac J Clin Nutr. 2008; 17(4): 573–579.
  32. Sugawara N, Yasui-Furukori N, Tsuchimine S, et al. Body composition in patients with schizophrenia: Comparison with healthy controls. Ann Gen Psychiatry. 2012; 11(1): 11.
  33. Konarzewska B, Stefańska E, Wendołowicz A, et al. Visceral obesity in normal-weight patients suffering from chronic schizophrenia. BMC Psychiatry. 2014; 14: 35.
  34. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012; 18(3): 363–374.
  35. Takeuchi H, Uchida H, Suzuki T, et al. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Psychiatry Clin Neurosci. 2010; 64(1): 104–106.
  36. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006; 163(10): 1821–1825.
  37. L'Italien GJ, Casey DE, Kan HJ, et al. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry. 2007; 68(10): 1510–1516.
  38. Virtanen KA, Iozzo P, Hällsten K, et al. Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. Diabetes. 2005; 54(9): 2720–2726.
  39. Skrede S, Fernø J, Vázquez MJ, et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol. 2012; 15(2): 163–179.
  40. Im SS, Kwon SK, Kang SY, et al. Regulation of GLUT4 gene expression by SREBP-1c in adipocytes. Biochem J. 2006; 399(1): 131–139.
  41. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond). 2009; 33(1): 151–156.
  42. Hivert MF, Sun Q, Shrader P, et al. Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia. 2009; 52(10): 2101–2108.
  43. Bosch M, Lopez-Bermejo A, Vendrell J, et al. Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia. 2005; 48(9): 1841–1843.
  44. Novick D, Dinarello CA, Dinarello CA, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999; 10(1): 127–136.